Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry and MaSTherCell Global, Inc. (“MaSTherCell Global”), a portfolio company and strategic partner of Great Point, today announce executive promotions at MaSTherCell Global effective January 1, 2019.
Greenwich, CT, US and Charleroi, Belgium, January 25, 2019 - Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry and MaSTherCell Global, Inc. (“MaSTherCell Global”), a portfolio company and strategic partner of Great Point, today announce executive promotions at MaSTherCell Global effective January 1, 2019.
Darren Head has been promoted to Chief Executive Officer of MaSTherCell Global, and Dr. Denis Bedoret has been promoted to President of MaSTherCell Global. Mr. Head has been the President of MaSTherCell Global since June 2018 and was previously the CEO of Cytovance Biologics, a biologics contract manufacturer that grew at a 45 percent compound annual growth rate during his leadership. Dr. Bedoret is the Managing Director of MaSTherCell S.A., the Belgium subsidiary of MaSTherCell Global (“MaSTherCell Belgium”) since March 2017 and has been leading the European operations through a rapid growth phase, including multiple facility expansions.
Vered Caplan, executive chairman at MaSTherCell Global stated, “Under Denis’ leadership, MaSTherCell Belgium has experienced tremendous success, and he has recently taken on additional operational and managerial responsibilities with oversight for the company’s Asian operations. Darren brings to MaSTherCell Global decades of executive experience in the life sciences industry and has provided great leadership to the company. We are excited to announce Darren and Denis’ promotions, and we look forward to working with them to further expand MaSTherCell Global’s presence as a leading provider of cell and gene therapy CDMO services.”
Noah Rhodes, managing director at Great Point Partners added, “Darren and Denis bring an enormous amount of talent, wisdom and experience to MaSTherCell Global, and we are excited to announce their well-deserved promotions. MaSTherCell Global has been on an aggressive growth trajectory, and in Darren and Denis’ very capable hands we will be further accelerating the pace of growth. It remains a privilege for GPP to work with Darren, Denis, and the entire global MaSTherCell Global team.”
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately USD 1.4 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has committed capital of USD 215 million. Great Point manages capital in private (GPP I, USD 156 million and GPP II, USD 215 million of committed capital, and GPP III with a target of USD 250 million in committed capital) and public (BioMedical Value Fund strategy, approximately USD 800 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971- 3300 or www.gppfunds.com.
About MaSTherCell Global
MaSTherCell Global is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. At the heart of MaSTherCell Global is a team of more than 150 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell Global’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. For more information, visit www.masthercell.com.
